Aker BioMarine Plans US NDI Notification For EPA/DHA Formulated To Pass Blood-Brain Barrier

Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.

Aker BioMarine's Lysoveta EPA/DHA formulation is bound by lysophosphatidylcholine to allow the fatty acids to pass through the blood-brain barrier via transporter Mfsd2a.

Aker BioMarine ASA expects to submit a new dietary ingredient notification in the US during 2022 for its krill oil fatty acids formulated to deliver targeted eye and brain health benefits by passing through the blood-brain barrier.

The eicapentaenoic acid (EPA) and docosapentaenoic acid (DHA) in ghe firm's Lysoveta formulation are bound by lysophosphatidylcholine (LPC) which allows...